Postural instability and gait difficulty (PIGD) features are among the most disabling motor features of Parkinson's disease (PD) and are least responsive to dopaminergic medications. 1, 2 There is a need to explore nondopaminergic mechanisms of PIGD, because the presence of PIGD features is a critical determinant of quality of life in PD. 3, 4 PD is a multisystem neurodegeneration syndrome manifesting with both motor and cognitive morbidity. There are several lines of evidence showing an intrinsic association between cognition and mobility in PD. First, the PIGD motor subtype is a risk factor for the development of dementia in PD (PDD). [5] [6] [7] Second, walking and/or maintaining upright balance is affected by concurrent cognitive tasks. 8 Third, cognitive impairment is a risk factor for falls. 9 Although some aspects of cognitive dysfunction are related to striatal dopaminergic deficits, 10 dopamine (DA) replacement therapy has mixed effects on cognition in PD. 11, 12 Given the ambiguous role of DA in the etiology of both PIGD features and cognitive impairment, nondopaminergic processes may underlie the relationship between cognition and PIGD features in PD.
In Alzheimer's disease (AD), deposition of b-amyloid (Ab) plaques occurs early in disease 13 and is associated with cognitive impairment.
14 Postmortem findings of Alzheimer's pathology are found also in the brains of PD patients, typically reflecting late-stage (and agerelated) pathology. 15 However, in vivo imaging studies of Ab using 11 C-Pittsburgh compound-B ([ 11 C]-PiB) PET generally show lower, more-variable levels of Ab in the neocortex of subjects with PD or PDD, when compared to AD. [16] [17] [18] [19] [20] The effect of neocortical Ab on clinical features of PD, particularly with respect to DA nonresponsive motor symptoms, has not been well studied. Given the severe striatal dopaminergic deficits of PD, it is possible that comorbid Ab pathology may aggravate specific clinical features of PD.
The aim of this study was to examine the relationship between neocortical Ab burden, estimated in vivo with [ 
Patients and Methods

Subjects
This cross-sectional study included 44 PD patients with either mild cognitive impairment symptoms or known risk factors for developing PD-associated dementia, specifically older age, longer disease duration, or evidence of PIGD features. 6, 21, 22 These patients underwent a [ 11 C]-PiB scan as part of a larger ongoing cohort study (National Institutes of Health P01 NS015655). Detailed demographic and disease severity information is provided in Table 1 .
Patients met the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria. 23 The diagnosis of PD was confirmed by the presence of a typical pattern of nigrostriatal dopaminergic denervation on [ 11 C]-DTBZ PET imaging. 24 All subjects were on DA replacement therapy (see also Table 1 ). None of the subjects were on anticholinergic or cholinesterase inhibitor drugs. Subjects were clinically examined and imaged in the morning after overnight withholding of their dopaminergic drugs.
Written informed consent was obtained from all subjects before research procedures. The University of Michigan Medical School Institutional Review Board (Ann Arbor, MI) for human studies approved the study.
Clinical Assessments
Clinical evaluations included PD motor feature assessment using the Movement Disorder Society revised UPDRS (MDS-UPDRS). 25, 26 The PIGD score was calculated as the sum of items 2.11 to 2.13 and 3.9 to 3.13, and a non-PIGD score was calculated as the sum of the non-PIGD items of parts II and III of the MDS-UPDRS. Cognitive capacity was assessed with the Dementia Rating Scale (DRS) 27 with subjects on their regular dopaminergic medications.
MRI
All subjects underwent brain MRI for anatomic coregistration with PET. MRI was performed on a 3 T Philips Achieva system (Philips, Best, The Netherlands) utilizing an eight-channel head coil and the ''ISOVOX'' exam card protocol primarily designed to yield isotropic spatial resolution. A standard T1-weighted series of a three-dimensional (3D) inversion recovery-prepared turbo field echo was performed in the sagittal plane using the following: repetition time/echo time/inversion time ¼ 9.8/4.6/1041 ms; turbo factor ¼ 200; single average; field of view ¼ 240 Â 200 Â 160 mm; and acquired matrix ¼ 240 Â 200. One hundred and sixty slices were reconstructed to 1-mm isotropic resolution.
PET Imaging
PET imaging was performed in 3D imaging mode using an ECAT HRþ tomograph (Siemens Molecular Imaging, Inc., Knoxville, TN), which acquires 63 transaxial slices (slice thickness ¼ 2.4 mm; intrinsic in-plane resolution ¼ 4.1 mm full width at half maximum over a 15.2-cm axial field of view). A NeuroShield (Scanwell Systems, Montreal, Quebec, Canada) head-holder/shielding unit was attached to the patient bed to reduce the contribution of detected photon events originating from the body outside the scanner Values represent mean 6 standard deviation (range). Abbreviation: CL, carbidopa-levodopa.
field of view. Before the radioligand injections, a 5-minute transmission scan was acquired using rotating 68 Ge rods for attenuation correction of emission data using the standard vendor-supplied segmentation and reprojection routines.
[
]-dihydrotetrabenazine) was prepared as reported previously. 28 [ 11 C]-DTBZ PET scans were performed using a bolus/ infusion protocol acquiring 15 emission scans over 60 minutes (4 Â 30 seconds; 3 Â 1 minute; 2 Â 2.5 minutes; 2 Â 5 minutes; and 4 Â 10 minutes), with a priming bolus of 55%, followed by continuous infusion of the remaining 45% over the study duration using a dose of 555 MBq.
[ ]-DTBZ scan sequence plus two additional 10-minute scans), with a priming bolus of 40%, followed by continuous infusion of the remaining 60% over the study duration using a dose of 666 MBq.
All subjects were studied supine, with eyes and ears unoccluded, resting quietly in a dimly lit room.
PET Analysis
All dynamic PET imaging frames were spatially coregistered within subjects with a rigid body transformation to reduce the effects of subject motion during the imaging session. 31 These motion-corrected PET frames were spatially coregistered to the MRI using SPM8 software (Wellcome Trust Center for Neuroimaging, London, UK). IDL image-analysis software (Research Systems, Inc., Boulder, CO) was used to manually trace volumes of interest (VOIs) on the MRI scan. Traced VOIs included the striatum (caudate and putamen), thalamus, cerebellum, and the neocortex. Neocortical VOI definition used semiautomated thresholding delineation of the neocortical gray-matter signal on MRI images.
Time-activity curves for each VOI were generated from the spatially aligned PET frames. 
Statistical Analysis
Variables were rank-order transformed to mitigate the effect of possible outliers. Linear regression analysis was performed to assess the association between PIGD subscore and neocortical [ 11 C]-PiB DVR while controlling for striatal [ 
Results
Descriptive results for the MDS-UPDRS, DRS, and PET ligands are presented in Table 2 . Subjects had mild to moderate motor disease severity and a mean DRS total score that was within the mildly impaired range. 33 Across all subjects, neocortical [
11 C]-PiB binding was generally in the low range, but regionally more elevated in the frontal and temporal lobes and the cingulate gyrus (Fig. 1) .
Linear regression analysis showed that neocortical [ 
Discussion
We examined the relationship between PIGD feature severity and neocortical Ab burden in PD patients with mild cognitive impairment or at risk for development of dementia. We found that increased PIGD feature severity was associated with increased neocortical Ab burden while controlling for the effect of possible confounding variables, such as the degree of striatal dopaminergic denervation, age, or the degree of cognitive capacity impairment. This was a PIGD featurespecific effect, because neocortical Ab burden did not have an association with non-PIGD feature severity. Furthermore, the results remained significant even after the exclusion of subjects with more-severe neocortical amyloidopathy. Subcortical Ab burden did not affect PIGD feature severity. Dopaminergic denervation is severe in PD, even at the onset of the disease. presence of severe striatal dopaminergic denervation, comorbid neocortical amyloidopathy may have exacerbating effects on gait and postural stability, even when the amyloidopathy is at below-AD level of Ab-binding levels. 35 This suggests that relatively low levels of comorbid neocortical Ab plaques are of pathophysiological significance in PD and may aggravate motor impairments of PD patients.
Further evidence for a possible role of cortical amyloidopathy on the etiology of balance and gait impairments can be found in AD patients. Subtle changes in balance and gait occur early in the course of AD. 36 Several studies have shown that gait and static standing balance characteristics of AD patients are different from healthy subjects. [37] [38] [39] These changes are especially evident when there are additional cognitive task demands while walking. [40] [41] [42] These observations support an intrinsic relationship between cognition and motor control functions and suggest a possible pathogenic role for neocortical amyloidopathy in gait dysfunction.
The cross-sectional study design and regression analyses were limitations of our study, because these do not allow for causal assessment of the relationship between PIDG feature severity and the degree of neocortical amyloidopathy. Prospective studies are needed to confirm that amyloidopathy is an important mechanism underlying both progression of PIGD motor features and cognitive decline in PD.
PD is a multisystem neurodegenerative disorder. 43 Our study shows that, in the presence of severe nigrostriatal dopaminergic denervation, even relatively low levels of comorbid neocortical amyloidopathy may augment gait and postural impairments in PD. These results and our recent findings of an association between cortical amyloidopathy and the degree of cognitive impairment in PD patients 44 suggest that cortical amyloidopathy may provide a common mechanism for PIGD features and cognitive impairment. This may explain why the PIGD motor phenotype is a risk factor for the development of PDD. Several promising therapies have been tested in AD patients that target Ab production, aggregation, or accumulation, which, likely, are most effective when applied to asymptomatic patients with very early signs of AD pathology. 45 Future studies could evaluate whether early treatment of amyloidopathy may modify the progression of PIGD features in PD.
